Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517152-34-00

Enrollment

Registered

2024-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irresectable peritoneal metastases of colorectal cancer

Brief summary

To determine the anti-tumor activity in patients treated with intraperitoneal irinotecan (75 mg) and concomitant palliative systemic therapy, in terms of overall survival (calculated from (a) the interval from diagnosis of peritoneal metastases until death or last follow-up; (b) the interval from the first day of the first cycle until death or last follow-up).

Interventions

DRUGIrinotecan Hydrochloride 20 mg/ml concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To determine the anti-tumor activity in patients treated with intraperitoneal irinotecan (75 mg) and concomitant palliative systemic therapy, in terms of overall survival (calculated from (a) the interval from diagnosis of peritoneal metastases until death or last follow-up; (b) the interval from the first day of the first cycle until death or last follow-up).	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026